| Title: | Association between PIK3CA activating mutations and outcomes in early-stage invasive lobular breast carcinoma treated with adjuvant systemic therapy |
|---|
| Authors: | ID Ribnikar, Domen (Author)
ID Jerič Horvat, Valentina (Author)
ID Ratoša, Ivica (Author)
ID Veitch, Zachary (Author)
ID Grčar-Kuzmanov, Biljana (Author)
ID Novaković, Srdjan (Author)
ID Langerholc, Erik (Author)
ID Amir, Eitan (Author)
ID Šeruga, Boštjan (Author) |
|---|
| Files: |  PDF - Presentation file, download (512,26 KB)
MD5: 3CB8288CAF8A7DD3294FB2EDCFBDF6AE
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  OI - Institute of Oncology
|
|---|
| Abstract: | The aim of the study was to evaluate the independent prognostic role of PIK3CA activating mutationsand an association between PIK3CA activating mutations and efficacy of adjuvant endocrine therapy (ET) in patientswith operable invasive lobular carcinoma (ILC).Patients and methods.A single institution study of patients with early-stage ILC treated between 2003 and 2008 wasperformed. Clinicopathological parameters, systemic therapy exposure and outcomes (distant metastasis-free sur-vival [DMFS] and overall survival [OS]) were collected based on presence or absence of PIK3CA activating mutationin the primary tumor determined using a quantitative polymerase chain reaction (PCR)-based assay. An associationbetween PIK3CA mutation status and prognosis in all patient cohort was analyzed by Kaplan-Meier survival analysis,whereas an association between PIK3CA mutation and ET was analyzed in estrogen receptors (ER) and/or progester-one receptors (PR)-positive group of our patients by the Cox proportional hazards model.Results. Median age at diagnosis of all patients was 62.8 years and median follow-up time was 10.8 years. Among365 patients, PIK3CA activating mutations were identified in 45%. PIK3CA activating mutations were not associatedwith differential DMFS and OS (p = 0.36 and p = 0.42, respectively). In patients with PIK3CA mutation each year oftamoxifen (TAM) or aromatase inhibitor (AI) decreased the risk of death by 27% and 21% in comparison to no ET, re-spectively. The type and duration of ET did not have significant impact on DMFS, however longer duration of ET hada favourable impact on OS.Conclusions. PIK3CA activating mutations are not associated with an impact on DMFS and OS in early-stage ILC.Patients with PIK3CA mutation had a statistically significantly decreased risk of death irrespective of whether theyreceived TAM or an AI. |
|---|
| Keywords: | invasive lobular carcinoma, PIK3CA mutation, endocrine therapy |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Publication date: | 01.01.2023 |
|---|
| Publisher: | Association of Radiology and Oncology |
|---|
| Year of publishing: | 2023 |
|---|
| Number of pages: | str. 220-228 |
|---|
| Numbering: | Vol. 57, no. 2 |
|---|
| Source: | Ljubljana |
|---|
| PID: | 20.500.12556/DiRROS-19835  |
|---|
| UDC: | 618.19-006 |
|---|
| ISSN on article: | 1318-2099 |
|---|
| DOI: | 10.2478/raon-2023-0027 |
|---|
| COBISS.SI-ID: | 159020291 |
|---|
| Copyright: | by Authors |
|---|
| Publication date in DiRROS: | 25.07.2024 |
|---|
| Views: | 363 |
|---|
| Downloads: | 113 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
